2166-33-8

Basic information

• Product Name: p-Anisylpyridazone
• Synonyms: p-Anisylpyridazone;6-(4-methoxyphenyl)pyridazin-3(2H)-one;6-(4-Methoxyphenyl)-3(2H)-pyridazinone;6-(p-Methoxyphenyl)-3(2H)-pyridazinone
• CAS NO: 2166-33-8
• Molecular Formula: C₁₁H₁₀N₂O₂
• Molecular Weight: 202.2093
• Product Categories: Aromatics;Heterocycles;Intermediates
• Mol File: 2166-33-8.mol
• Article Data: 19

Chemical Properties

• Melting Point: 188-189 °C
• Appearance: /
• Density: 1.22±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Dichloromethane, Methanol
• PKA: 11.08±0.40(Predicted)
• CAS DataBase Reference: p-Anisylpyridazone(CAS DataBase Reference)
• NIST Chemistry Reference: p-Anisylpyridazone(2166-33-8)
• EPA Substance Registry System: p-Anisylpyridazone(2166-33-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 2166-33-8(Hazardous Substances Data)

Usage

Description

p-Anisylpyridazone is a white to yellow solid that serves as an intermediate in the synthesis of various pharmaceuticals, including the drug Gabazine and several analgesic medications.

Uses

Used in Pharmaceutical Industry:
p-Anisylpyridazone is used as a key intermediate in the synthesis of Gabazine, a GABA-A receptor antagonist, for its application in treating neurological disorders and as an adjunct in anesthesia.
Additionally, p-Anisylpyridazone is utilized in the production of several analgesic pharmaceuticals, contributing to the development of pain-relief medications and enhancing their efficacy in managing various types of pain.

Upstream product

• 1017-06-7 6-(4-Methoxyphenyl)-4,5-dihydro-2H-pyridazin-3-one 
• 298-12-4 Glyoxilic acid 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 1316302-31-4 ethyl 2-benzoyl-4-(4-methoxyphenyl)-4-oxobut-2-enoate 
• 862816-15-7 4-(4-methoxy)phenyl-2-hydroxy-4-oxobutyric acid ethyl ester 
• 1010800-67-5 tert-butyl 4-(4-methoxyphenyl)-4-oxobutanoate 
• 3153-44-4 4-(4-methoxy-phenyl)-4-oxo-butyric acid 

Downstream Products

• 87741-48-8 4-Cyano-benzoic acid 6-(4-methoxy-phenyl)-pyridazin-3-yl ester 
• 87741-41-1 Benzoesaeure-<6-(4-methoxy-phenyl)-pyridazin-3-yl-ester> 
• 87741-42-2 4-Chlor-benzoesaeure-<6-(4-methoxy-phenyl)-pyridazin-3-yl-ester> 
• 87741-46-6 4-Methoxy-benzoesaeure-<6-(4-methoxy-phenyl)-pyridazin-3-yl-ester> 
• 87741-44-4 4-Nitro-benzoesaeure-<6-(4-methoxy-phenyl)-pyridazin-3-yl-ester> 
• 75616-16-9 6-(4-Methoxy-phenyl)-6-phenyl-1,6-dihydro-2H-pyridazin-3-one 
• 282090-13-5 3-[6-(4-methoxyphenyl)-3(2H)-pyridazinon-2-yl]propanenitrile 
• 87741-43-3 4-Brom-benzoesaeure-<6-(4-methoxy-phenyl)-pyridazin-3-yl-ester> 
• 87741-45-5 4-Hexyl-benzoesaeure-<6-(4-methoxy-phenyl)-pyridazin-3-yl-ester> 
• 87741-47-7 4-Hexyloxy-benzoic acid 6-(4-methoxy-phenyl)-pyridazin-3-yl ester 
• 58059-31-7 3-chloro-6-(4-methoxyphenyl)pyridazine 
• 133342-12-8 ethyl [6-(4-methoxyphenyl)-3(2H)-pyridazinon-2-yl]acetate 

Relevant articles and documents

Novel pyridazinone derivatives as butyrylcholinesterase inhibitors

In the current study, forty-four new [3-(2/3/4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl]methyl carbamate derivatives were synthesized and evaluated for their ability to inhibit electric eel acetylcholinesterase (EeAChE) and equine butyrylcholinesterase (eqB

Rhodium(III)-Catalyzed Alkynylation of 4-Arylphthalazin-1(2H)-one Scaffolds via C-H Bond Activation

Selective C–H bond alkynylation toward modular access to material and pharmaceutical molecules is of great desire in modern organic synthesis. Disclosed herein is rhodium(III)-catalyzed selective C–H bond mono-/bialkynylation of 4-aryl phthalazin-1(2H)-one was developed. The silver salt AgSbF6 are demonstrated to play a vital role in promoting the bialkynylation reactions. The present alkynylation strategy is simple, efficient, and features high functional group tolerance and broad substrate scope under an air atmosphere. Additionally, 6-aryl pyridazin-3(2H)-one scaffold is amenable to the selective monoalkynylation and sequential bialkynylation, respectively.

Phosphodiesterase inhibitors. Part 5: Hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration

(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl) -5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory activity and promises as a combined bronchodilatory/anti- inflammatory agent. N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition. Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent PDE3 inhibition. Both dihydropyridazinone rings, in the core and extension, can be replaced by achiral 4,4-dimethylpyrazolone subunits and the core pyrazolopyridine by isosteric bicyclic heteroaromatics. In combination, these modifications afford potent dual PDE3/4 inhibitors that suppress histamine-induced bronchoconstriction in vivo and exhibit promising anti-inflammatory activity via intratracheal administration.